TRIO-US B-12 TALENT (NCT04553770) is a phase 2 neoadjuvant trial conducted in 2020 to investigate DS-8201 with or without anastrozole for HER2-low, HR-positive early-stage breast cancer [71]. Here, ERBB2 is linked to breast carcinoma.